Results 91 to 100 of about 35,525 (153)

Comparative Effectiveness of Sodium-Glucose Co-transporter 2 Inhibitors and Thiazolidinediones in Reducing Adverse Cardiovascular Events in Type 2 Diabetes. [PDF]

Cureus
Ali A, Sohail U, Rao T, Tariq F, Baig AM, Fatima SA.   +5 more
europepmc   +1 more source

Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case Series

Turkish Journal of Hematology
Pusem Patır, Kübra Çerçi, Erdal Kurtoğlu   +2 more
doaj   +1 more source

Association between sodium-glucose co-transporter-2 inhibitors and cardiac outcomes in cancer patients: a systematic review and meta-analysis. [PDF]

J Geriatr Cardiol
Zheng XY, Zhang N, Xie BX, Li GP, Zhou JD, Tse G, Liu T.   +6 more
europepmc   +1 more source

Can Sodium-Glucose Co-Transporter-2 Inhibitors Improve Sleep Quality, Anxiety, and Quality of Life in Patients With Heart Failure? [PDF]

Clin Cardiol
Erbay I, Gudul NE, Suner AF, Aladag P, Karacar U, Avci A.   +5 more
europepmc   +1 more source

Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature Review. [PDF]

Adv Ther
Handelsman Y, Cheng AYY, Fadini GP, Kushner P, Bonnet F, Fioretto P, Kadowaki T, Kanumilli N, Cos X, Frese T, Ji L, Murton M, Foulcer S, Pentakota S, Rossing P.   +14 more
europepmc   +1 more source

The influence of sodium-glucose co-transporter-2 inhibitors on the risk of cancer therapy-related cardiac dysfunction: A meta-analysis. [PDF]

Biomol Biomed
Yan Z, Xing X, Huang J.
europepmc   +1 more source

A cross-sectional survey of knowledge regarding sodium-glucose co-transporter 2 inhibitors (SGLT2is) among primary care physicians and pharmacists in China. [PDF]

J Pharm Health Care Sci
Dong Y, Zheng S, Wang W, Wang D, Wang H, Xiang C.   +5 more
europepmc   +1 more source

Sodium-glucose co-transporter 2 inhibitors in severe estimated glomerular filtration rate deterioration across cardiovascular-kidney- metabolic conditions: A pooled analysis of randomized trials. [PDF]

Eur J Heart Fail
Ferreira JP, Marques P, Anker SD, Butler J, Filippatos G, Sharma A, Vasques-Nóvoa F, Mendonça L, Neves JS, Packer M, Zannad F.   +10 more
europepmc   +1 more source

Impact of Sodium-Glucose Co-transporter 2 Inhibitors After Discharge in Patients With Heart Failure With Reduced Activities of Daily Living: A Single-Center Retrospective Cohort Study. [PDF]

Cureus
Suzuki M, Akiyama S, Saito H, Matsui H, Funakoshi R.   +4 more
europepmc   +1 more source

Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies. [PDF]

Eur Heart J Cardiovasc Pharmacother
Laborante R, Elia S, Savarese G, Patti G, D'Amario D.   +4 more
europepmc   +1 more source